Bristol-Myers Squ…
USUSDBristol-Myers Squibb Company (US:BMY) — Drug Manufacturers - General. Biržu skaits, kurās tiek tirgotas uzņēmuma akcijas: 6. Šajā lapā — cena un grafiks, dividendes, lielākie akcionāri un akciju skaita vēsture.
Par Uzņēmumu
- Tīmekļvietne
- bms.com
- Investoru Attiecības
- bms.com/investors.html
- Nozare
- Healthcare · Drug Manufacturers - General
- Galvenā Mītne
- PRINCETON, United States
- Izpilddirektors
- Christopher S. Boerner
- Darbinieki
- 32 500
- Dibināts
- 1989
- Apgrozībā Esošās Akcijas
- 2.04 mljrd. uz 2026-07-22
- Brīvā Apgrozība
- 2.04 mljrd.
- Tirgus Kapitalizācija
- 128.41 mljrd. USD
- Iekšējās Personas
- 0.1%
- Institucionālie Investori
- 84.87%
- Nozare (SIC)
- Pharmaceutical Preparations
- Juridiskā Forma
- XTIQ
- ISIN
- US1101221083
- LEI
- HLYYNH7UQUORYSJQCN42
- P/E
- 12.7
- Izmaksas Koeficients
- 54.9%
- FCF
- 11.4 mljrd. USD
- Izmaksas / FCF
- 45%
- Parāds
- 43.9 mljrd. USD3.1 g. FCF
- Dividenžu Stāžs
- 54 g.
- Peļņa, FCF un izmaksātās dividendes — par 12 mēnešiem līdz 30.06.2026 (uzņēmuma jaunākais ziņojums).
Apraksts
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Biržas un Tikeri
| Birža | Tikeris | Valūta | Cena | Veids |
|---|---|---|---|---|
| US USA Stocks | BMY galvenā | USD | 57.58 -2.60% | parastās akcijas |
| LSE London Stock Exchange | 0R1F IOB | GBP | — | parastās akcijas |
| MI Borsa Italiana (Milan) | 1BMY papildu | EUR | 53.13 +0.28% | parastās akcijas |
| MX Mexican Stock Exchange | BMY papildu | MXN | 1 047 -3.81% | parastās akcijas |
| VI Vienna Stock Exchange | BMYS papildu | EUR | 52.98 +0.34% | parastās akcijas |
| XETRA Xetra | BRM papildu | EUR | 53.04 +0.89% | parastās akcijas |
Dividendes
Bristol-Myers Squibb Company (BMY) izmaksā dividendes reizi ceturksnī. Gadā (12 mēneši līdz jaunākajam paziņotajam maksājumam): 2.52 USD par akciju (maksājumi: 4). Tas ir aptuveni 4.38% no pašreizējās akciju cenas. Pamatojoties uz maksājumu vēsturi, nākamais ex-dividendes datums tiek gaidīts ap 01.01.2027. Nepārtrauktu dividenžu gadi: 54.
| Ex-Datums | Izmaksa | Summa | % | Veids | Tikeris |
|---|---|---|---|---|---|
| 2026-10-02 | 2026-11-02 | 0.6300 USD | 1.0/4.1 % | ceturkšņa | US:BMY |
| 2026-07-02 | 2026-08-03 | 0.6300 USD | 1.1/4.4 % | ceturkšņa | US:BMY |
| 2026-04-02 | 2026-05-01 | 0.6300 USD | 1.0/4.0 % | ceturkšņa | US:BMY |
| 2026-01-02 | 2026-02-02 | 0.6300 USD | 1.2/4.6 % | ceturkšņa | US:BMY |
| 2025-10-03 | 2025-11-03 | 0.6200 USD | 1.4/5.4 % | ceturkšņa | US:BMY |
| 2025-07-03 | 2025-08-01 | 0.6200 USD | 1.3/5.2 % | ceturkšņa | US:BMY |
| 2025-04-04 | 2025-05-01 | 0.6200 USD | 1.1/4.2 % | ceturkšņa | US:BMY |
| 2025-01-03 | 2025-02-03 | 0.6200 USD | 1.1/4.3 % | ceturkšņa | US:BMY |
| 2024-10-04 | 2024-11-01 | 0.6000 USD | 1.0/4.2 % | ceturkšņa | US:BMY |
| 2024-07-05 | 2024-08-01 | 0.6000 USD | 1.0/≈4.2 % | ceturkšņa | US:BMY |
| 2024-04-04 | 2024-05-01 | 0.6000 USD | 1.0/≈4.2 % | ceturkšņa | US:BMY |
| 2024-01-04 | 2024-02-01 | 0.6000 USD | 1.0/≈4.2 % | ceturkšņa | US:BMY |
Ziņas Šonedēļ
Preses relīzes no uzņēmuma investoru mājaslapas, kas tiek atjauninātas katru dienu. Saites ved uz uzņēmuma mājaslapu. Virsraksti ir oriģinālvalodā, kā uzņēmuma mājaslapā.
Lielākie Akcionāri
| Turētājs | Daļa | Akcijas | Pārskata Datums |
|---|---|---|---|
| Blackrock Inc. | 8.83% | 180.38 milj. | 2026-06-30 |
| Vanguard Capital Managem… | 6.53% | 133.34 milj. | 2026-06-30 |
| State Street Corporation | 5.01% | 102.41 milj. | 2026-06-30 |
| JPMORGAN CHASE & CO | 3.51% | 71.71 milj. | 2026-06-30 |
| Charles Schwab Investmen… | 3.31% | 67.6 milj. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 64.83 milj. | 2026-06-30 |
| Geode Capital Management… | 2.76% | 56.44 milj. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 52.92 milj. | 2026-06-30 |
| SCHWAB STRATEGIC TRUST-S… | 2.38% | 48.64 milj. | 2026-05-31 |
| Vanguard Portfolio Manag… | 2.29% | 46.87 milj. | 2026-06-30 |
| NORGES BANK | 1.8% | 36.87 milj. | 2026-06-30 |
| Bank of America Corporat… | 1.67% | 34.05 milj. | 2026-06-30 |
| Price (T.Rowe) Associate… | 1.55% | 31.71 milj. | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 27.55 milj. | 2026-08-31 |
| Fidelity Concord Street… | 1.29% | 26.41 milj. | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 24.96 milj. | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 19.44 milj. | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 14.68 milj. | 2026-08-31 |
| VANGUARD CHESTER FUNDS-V… | 0.7% | 14.29 milj. | 2026-06-30 |
| VANGUARD INSTITUTIONAL I… | 0.54% | 11.09 milj. | 2026-06-30 |
| LEUNG SANDRA (General Co… | ≈0.02% | 465 374 | 2025-03-10 |
| ELKINS DAVID VINCENT (Ch… | ≈0.01% | 159 542 | 2026-04-01 |
| BOERNER CHRISTOPHER S (C… | ≈0.01% | 146 890 | 2026-03-10 |
| HIRAWAT SAMIT (Officer) | ≈0% | 83 513 | 2025-04-25 |
| HALLER JULIA A (Director… | ≈0% | 34 079 | 2026-06-15 |
| MEYERS GREGORY SCOTT (Ch… | ≈0% | 30 361 | 2026-03-10 |
| LENKOWSKY ADAM (Officer) | ≈0% | 28 677 | 2026-05-01 |
| SHANAHAN KARIN (Officer) | ≈0% | 27 345 | 2026-04-01 |
| PLENGE ROBERT M (Officer… | ≈0% | 24 754 | 2026-03-10 |
| MASSACESI CRISTIAN (Offi… | ≈0% | 18 748 | 2026-09-09 |
